{"id":50349,"date":"2025-12-10T21:52:00","date_gmt":"2025-12-10T13:52:00","guid":{"rendered":"https:\/\/flcube.com\/?p=50349"},"modified":"2025-12-10T21:52:01","modified_gmt":"2025-12-10T13:52:01","slug":"fda-omisirge-severe-aplastic-anemia-first-hsct","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50349","title":{"rendered":"FDA Omisirge Severe Aplastic Anemia First HSCT"},"content":{"rendered":"\n<p>The <strong>US Food and Drug Administration (FDA)<\/strong> approved <strong>Omisirge (omidubicel-onlv)<\/strong> as the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with <strong>severe aplastic anemia (SAA)<\/strong>. The approval expands Omisirge&#8217;s indication to include adults and pediatric patients six years and older with SAA following reduced intensity conditioning, for whom a compatible donor is not available.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-clinical-data\">Regulatory Milestone &amp; Clinical Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Omisirge (omidubicel-onlv)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Gamida Cell Ltd.<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA approved (first HSCT therapy for SAA)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Severe aplastic anemia (SAA) in patients \u22656 years<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Ongoing, open-label, prospective, single-arm study<\/td><\/tr><tr><td><strong>Efficacy Population<\/strong><\/td><td>14 patients<\/td><\/tr><tr><td><strong>Neutrophil Engraftment<\/strong><\/td><td>12 of 14 patients (85.7%)<\/td><\/tr><tr><td><strong>Median Time to Recovery<\/strong><\/td><td>11 days (range 7-20 days)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-product-differentiation\">Mechanism of Action &amp; Product Differentiation<\/h2>\n\n\n\n<p><strong>Omisirge Technology:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stem Cell Source<\/strong>: Donated umbilical cord blood stem cells<\/li>\n\n\n\n<li><strong>Enhancement<\/strong>: Chemically enhanced with nicotinamide (vitamin B3)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Restores blood and immune system function<\/li>\n<\/ul>\n\n\n\n<p><strong>Addresses Key Limitations:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Delayed Hematopoietic Recovery<\/strong>: Omisirge provides early and sustained neutrophil engraftment<\/li>\n\n\n\n<li><strong>Infection Risk<\/strong>: Reduces infection risk vs. standard umbilical cord transplant<\/li>\n\n\n\n<li><strong>Donor Availability<\/strong>: Provides graft option when matched sibling or related donor unavailable<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-unmet-medical-need\">Market Context &amp; Unmet Medical Need<\/h2>\n\n\n\n<p><strong>Severe Aplastic Anemia (SAA):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare, life-threatening<\/strong> blood disorder where bone marrow fails to produce red blood cells, white blood cells, and platelets<\/li>\n\n\n\n<li><strong>Treatment Options<\/strong>: Immunosuppressive therapy and\/or HSCT (preferably from matched sibling donor)<\/li>\n\n\n\n<li><strong>Donor Limitation<\/strong>: ~70% of patients lack compatible matched donor<\/li>\n\n\n\n<li><strong>Current Gap<\/strong>: Umbilical cord transplant limited by slow recovery and infection risk<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Impact:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Omisirge offers first approved alternative for donor-unavailable SAA patients<\/li>\n\n\n\n<li>Provides rapid neutrophil recovery (median 11 days vs. 21-28 days with standard UCB)<\/li>\n\n\n\n<li>Reduces transplant-related mortality<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-gamida-cell-positioning\">Strategic Outlook &amp; Gamida Cell Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing<\/strong>: Leverages established Omisirge production platform<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Builds on existing hematologic malignancy distribution network<\/li>\n\n\n\n<li><strong>Revenue Expansion<\/strong>: SAA indication doubles addressable patient population<\/li>\n\n\n\n<li><strong>Next Milestones<\/strong>: Real-world evidence generation; potential pediatric expansion studies<\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong>: First and only approved product for SAA HSCT; 7+ years patent protection<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Omisirge&#8217;s commercial launch timeline, market penetration, and real-world outcomes. Actual results may differ due to manufacturing capacity, competitive dynamics, and reimbursement uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50352,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,4496,15],"class_list":["post-50349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-gamida-cell","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Omisirge Severe Aplastic Anemia First HSCT - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). The approval expands Omisirge&#039;s indication to include adults and pediatric patients six years and older with SAA following reduced intensity conditioning, for whom a compatible donor is not available.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50349\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Omisirge Severe Aplastic Anemia First HSCT\" \/>\n<meta property=\"og:description\" content=\"The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). The approval expands Omisirge&#039;s indication to include adults and pediatric patients six years and older with SAA following reduced intensity conditioning, for whom a compatible donor is not available.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50349\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T13:52:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-10T13:52:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Omisirge Severe Aplastic Anemia First HSCT\",\"datePublished\":\"2025-12-10T13:52:00+00:00\",\"dateModified\":\"2025-12-10T13:52:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349\"},\"wordCount\":357,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1003.webp\",\"keywords\":[\"Cell-therapy\",\"Gamida Cell\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50349#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50349\",\"name\":\"FDA Omisirge Severe Aplastic Anemia First HSCT - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1003.webp\",\"datePublished\":\"2025-12-10T13:52:00+00:00\",\"dateModified\":\"2025-12-10T13:52:01+00:00\",\"description\":\"The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). The approval expands Omisirge's indication to include adults and pediatric patients six years and older with SAA following reduced intensity conditioning, for whom a compatible donor is not available.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50349\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1003.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA Omisirge Severe Aplastic Anemia First HSCT\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50349#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Omisirge Severe Aplastic Anemia First HSCT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Omisirge Severe Aplastic Anemia First HSCT - Insight, China&#039;s Pharmaceutical Industry","description":"The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). The approval expands Omisirge's indication to include adults and pediatric patients six years and older with SAA following reduced intensity conditioning, for whom a compatible donor is not available.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50349","og_locale":"en_US","og_type":"article","og_title":"FDA Omisirge Severe Aplastic Anemia First HSCT","og_description":"The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). The approval expands Omisirge's indication to include adults and pediatric patients six years and older with SAA following reduced intensity conditioning, for whom a compatible donor is not available.","og_url":"https:\/\/flcube.com\/?p=50349","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-10T13:52:00+00:00","article_modified_time":"2025-12-10T13:52:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50349#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50349"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Omisirge Severe Aplastic Anemia First HSCT","datePublished":"2025-12-10T13:52:00+00:00","dateModified":"2025-12-10T13:52:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50349"},"wordCount":357,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50349#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1003.webp","keywords":["Cell-therapy","Gamida Cell","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50349#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50349","url":"https:\/\/flcube.com\/?p=50349","name":"FDA Omisirge Severe Aplastic Anemia First HSCT - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50349#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50349#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1003.webp","datePublished":"2025-12-10T13:52:00+00:00","dateModified":"2025-12-10T13:52:01+00:00","description":"The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). The approval expands Omisirge's indication to include adults and pediatric patients six years and older with SAA following reduced intensity conditioning, for whom a compatible donor is not available.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50349#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50349"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50349#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1003.webp","width":1080,"height":608,"caption":"FDA Omisirge Severe Aplastic Anemia First HSCT"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50349#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Omisirge Severe Aplastic Anemia First HSCT"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1003.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50349"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50349\/revisions"}],"predecessor-version":[{"id":50353,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50349\/revisions\/50353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50352"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}